Strategies to improve posttransplant immunity - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 132

References
[1] Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hema-
topoietic stem cell transplantation: a global perspective. JAMA 2010;303(16):1617-24.
Epub 2010/04/29.
[2] Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH, et al.
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone
marrow transplantation: effect of patient age and donor leukocyte infusions. Blood
1999;93(2):467-80.
[3] Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in
long-term survivors of allogeneic marrow transplantation is associated with low CD4 T
cell counts. Am J Hematol 1997;54(2):131-8.
[4] Storek J, Joseph A, Espino G, Dawson MA, Douek DC, Sullivan KM, et al. Immunity of
patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplan-
tation. Blood 2001;98(13):3505-12.
[5] Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplan-
tation into adult patients does not resemble T cell development in early life. Bone
Marrow Transplant 1995;16(3):413-25.
[6] Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al. Impact of T-cell
depletion on outcome of allogeneic bone-marrow transplantation for standard-risk
leukaemias. Lancet 1987;2(8552):175-8. Epub 1987/07/25.
[7] Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, et al. Solid cancers
after bone marrow transplantation. N Engl J Med 1997;336(13):897-904.
[8] Davies SM, Shu XO, Blazar BR, Filipovich AH, Kersey JH, Krivit W, et al. Unrelated donor
bone marrow transplantation: influence of HLA A and B incompatibility on outcome.
Blood 1995;86(4):1636-42.
[9] Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS, et al. The outcome
of matched unrelated donor bone marrow transplantation in patients with hemato-
logic malignancies using molecular typing for donor selection and graft-versus-host
disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood
1995;86(3):1228-34.
[10] Speiser DE, Tiercy JM, Rufer N, Grundschober C, Gratwohl A, Chapuis B, et al. High
resolution HLA matching associated with decreased mortality after unrelated bone
marrow transplantation. Blood 1996;87(10):4455-62.
[11] Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB, et al.
Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoi-
etic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor
Program Experience. Blood 2001;98(10):2922-9.
[12] Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M,
et al. Impact of HLA class I and class II high-resolution matching on outcomes of unre-
lated donor bone marrow transplantation: HLA-C mismatching is associated with a strong
adverse effect on transplantation outcome. Blood 2004;104(7):1923-30.
[13] Barker JN, Hough RE, van Burik JA, DeFor TE, MacMillan ML, O'Brien MR, et al. Serious
infections after unrelated donor transplantation in 136 children: impact of stem cell
source. Biol Blood Marrow Transplant 2005;11(5):362-70.
[14] Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A, et al. Late infections after
allogeneic bone marrow transplantations: comparison of incidence in related and
unrelated donor transplant recipients. Blood 1995;86(10):3979-86.
[15] Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in alloge-
neic stem cell transplant recipients: changes in epidemiology and risk factors. Blood
2002;100(13):4358-66. Epub 2002/10/24.
[16] Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G, et al. Immune reconstitution
following T-cell depleted bone marrow transplantation: effect of age and posttransplant
graft rejection prophylaxis. Biol Blood Marrow Transplant 1997;3(2):65-75.
[17] Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of
patients who may benefit from prophylactic immunotherapy after bone marrow trans-
plantation for acute myeloid leukemia on the basis of lymphocyte recovery early after
transplantation. Blood 1998;91(9):3481-6.
[18] Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L, et al. Absolute lymphocyte
count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts
outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow
Transplant 2007;13(10):1216-23. Epub 2007/09/25.
[19] Chakrabarti S, Brown J, Guttridge M, Pamphilon DH, Lankester A, Marks DI. Early
lymphocyte recovery is an important determinant of outcome following allogeneic
transplantation with CD34 + selected graft and limited T-cell addback. Bone Marrow
Transplant 2003;32(1):23-30.

134